Kineta, the Seattle-based drug developer, said today it has received a $1 million contract extension from the National Institutes of Health to mine existing computer databases to find new drug targets and candidates. The first part of the contract was designed to set up computational infrastructure for the project, which involves collaborators at the University of Washington, UC Irvine, University of Oregon, and University of Utah. The project is focused on five disease categories, Kineta said, including cardiovascular, neurological, infectious disease, metabolic disorders, and autoimmunity.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
